The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vaccine

• Publication date

  2010-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2009.12.026PMID 20044050
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006.

  2009cited by this paper
• Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

  2009cited by this paper
• IMPACT after 17 years: Lessons learned about successful networking.

  2009cited by this paper
• Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.

  2009cited by this paper
• The Changing Burden of Pediatric Bloodstream Infections in Calgary, Canada, 2000–2006

  2009cited by this paper
• Serotype replacement in perspective.

  2009cited by this paper
• A case of necrotizing fasciitis due to Streptococcus pneumoniae serotype 5 in Saskatchewan.

  2008cited by this paper
• Pneumonia After Implementation of the Pneumococcal Conjugate Vaccine Program in the Province of Quebec, Canada

  2008cited by this paper
• Impact of conjugate pneumococcal vaccines on antibiotic resistance.

  2008cited by this paper
• Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population.

  2008cited by this paper
• Replacement pneumococcal disease in perspective.

  2008cited by this paper
• Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

  2008cited by this paper
• Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae--United States, 2006-2007.

  2008cited by this paper
• Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005

  2007cited by this paper
• Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

  2007cited by this paper
• MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITORS OF METALLOPROTEINASES 1 IN INFLUENZA-ASSOCIATED ENCEPHALOPATHY

  2007cited by this paper
• Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

  2007cited by this paper
• Invasive pneumococcal infections in Canadian children, 1998-2003: implications for new vaccination programs.

  2007cited by this paper
• Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States

  2007cited by this paper
• Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae--Massachusetts, 2001-2006.

  2007cited by this paper
• Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.

  2006cited by this paper
• Immunization coverage by age 2 for five recommended vaccines in the Capital Health region (Edmonton).

  2006cited by this paper
• Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002-2005).

  2006cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Progress in the prevention of pneumococcal infection

  2005cited by this paper
• Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.

  2005cited by this paper
• Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.

  2004cited by this paper
• Post-PCV7 Changes in Colonizing Pneumococcal Serotypes in 16 Massachusetts Communities, 2001 and 2004

  2004cited by this paper
• Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

  2003cited by this paper
• An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.

  2002cited by this paper
• Multinational study of pneumococcal serotypes causing acute otitis media in children

  2002cited by this paper
• Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.

  2002cited by this paper
• Reduced susceptibility to penicillin among pneumococci causing invasive infection in children - Canada, 1991 to 1998.

  2001cited by this paper
• Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

  2001cited by this paper
• Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

  2000cited by this paper
• The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995.

  1998cited by this paper
• Bacterial Meningitis in the United States in 1995

  1997cited by this paper
• Bacterial meningitis in the United States in 1995. Active Surveillance Team.

  1997cited by this paper
• Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease.

  1996cited by this paper
• A case of necrotizing fasciitis due to Streptococcus pnewnoniae

  1995cited by this paper
• Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies.

  1995cited by this paper
• Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.

  1983cited by this paper

• Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007-23).

  2025cites this paper
• Streptococcus pneumoniae-associated hemolytic uremic syndrome Canadian Immunization Monitoring Program ACTive National Pediatric Surveillance (1991 to 2019)

  2024cites this paper
• Invasive pneumococcal disease surveillance in Canada, 2021–2022

  2024cites this paper
• Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2020.

  2023cites this paper
• Genomic analysis of Streptococcus pneumoniae serogroup 20 isolates in Alberta, Canada from 1993–2019

  2023cites this paper
• Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population

  2023cites this paper
• Clonal diversity of Streptococcus pneumoniae serotype 19A collected from children < 5 years old in Québec, Canada, 2016-2021.

  2023cites this paper
• Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020.

  2023cites this paper
• Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20.

  2023cites this paper
• Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-2020.

  2023cites this paper
• Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network

  2022cites this paper
• Invasive pneumococcal disease surveillance in Canada, 2020.

  2022cites this paper
• Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.

  2022cites this paper
• Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018.

  2021cites this paper
• Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018.

  2021cites this paper
• Objective of the Peads Network to Evaluate the Performance of Active Monitoring of Children Hospital Encephalitis

  2021cites this paper
• Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia

  2021cites this paper
• Bacterial Meningitis in Children: Neurological Complications, Associated Risk Factors, and Prevention

  2021cites this paper
• Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia

  2020cites this paper
• Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations

  2020cites this paper
• Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

  2020cites this paper
• Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis

  2020cites this paper
• Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017.

  2020cites this paper
• Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).

  2019cites this paper
• Epidemiological characteristics of nasopharyngeal Streptococcus pneumoniae strains among children with pneumonia in Chongqing, China

  2019cites this paper
• Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.

  2019cites this paper
• The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017

  2019cites this paper
• 46 – Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines

  2018cites this paper
• Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada

  2018cites this paper
• Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

  2018cites this paper
• Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

  2018cites this paper
• Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

  2018cites this paper
• Multi-target plasmid controls for conventional and real-time PCR-based serotyping of Streptococcus pneumoniae.

  2018cites this paper
• Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study.

  2017cites this paper
• Discrimination of vaccine preventable serotypes of Streptococcus pneumoniae by PCR and sequencing

  2017cites this paper
• Assessing the diagnostic accuracy of PCR-based detection of Streptococcus pneumoniae from nasopharyngeal swabs collected for viral studies in Canadian adults hospitalised with community-acquired pneumonia: a Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research (CIRN) stu

  2017cites this paper
• Whole-genome Based Investigation of Streptococcus pneumoniae Infections

  2017influential citation
• Long-term trends in invasive pneumococcal disease in Manitoba, Canada

  2017cites this paper
• Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis

  2017cites this paper
• A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada

  2016cites this paper
• Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.

  2016cites this paper
• Pneumococcal conjugate vaccine failure in children: A systematic review of the literature.

  2016cites this paper
• Clinical and pathogenic analysis of 507 children with bacterial meningitis in Beijing, 2010-2014.

  2016cites this paper
• Population Structure of Streptococcus pneumoniae Causing Invasive Disease in Adults in Portugal before PCV13 Availability for Adults: 2008-2011

  2016cites this paper
• Refining PCR-based serotyping for detection of vaccine-preventable Streptococcus pneumoniae

  2016cites this paper
• A retrospective study of the clinical burden of hospitalized all-cause and pneumococcal pneumonia in Canada.

  2015cites this paper
• Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough

  2015cites this paper
• Experience of application and safety assessment of the 13-valent pneumococcal conjugate vaccine in under-5 children

  2015cites this paper
• Genetic Analysis of Invasive Pneumococcal Isolates from Children in Ontario, Canada, 2007–2012

  2015cites this paper
• Effectiveness of the standard and an alternative set of Streptococcus pneumoniae multi locus sequence typing primers

  2014cites this paper
• Effect of Pneumococcal Conjugate Vaccination in Uruguay, a Middle-Income Country

  2014cites this paper
• Serotypes and Genotypes of Invasive Streptococcus pneumoniae Before and After PCV10 Implementation in Southern Brazil

  2014cites this paper
• Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009–2012

  2014cites this paper
• Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age.

  2014cites this paper
• Lignes directrices pour la prise en charge de la méningite bactérienne présumée ou confirmée chez les enfants canadiens de plus d’un mois

  2014cites this paper
• Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010.

  2014cites this paper
• Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age

  2014cites this paper
• Serotypes and antimicrobial resistance of invasive Streptococcus pneumoniae isolates from East Algeria (2005-2011)

  2014influential citation
• Trends in Asymptomatic Nasopharyngeal Colonization With Streptococcus pneumoniae After Introduction of the 13-valent Pneumococcal Conjugate Vaccine in Calgary, Canada

  2014cites this paper
• Microbial pollution of the Mezam river system and its health impact in Bamenda (North-West Cameroon)

  2013cites this paper
• The burden and impact of severe and long-term sequelae of meningococcal disease

  2013cites this paper
• Why Do We Need a Systematic Review of Pneumococcal Conjugate Vaccine Dosing Schedules?

  2013cites this paper
• The Majority of Adult Pneumococcal Invasive Infections in Portugal Are Still Potentially Vaccine Preventable in Spite of Significant Declines of Serotypes 1 and 5

  2013cites this paper
• Systematic Review of the Indirect Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Pneumococcal Disease and Colonization

  2013cites this paper
• Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

  2013cites this paper
• Have changing pneumococcal vaccination programmes impacted disease in Ontario?

  2013cites this paper
• Streptococcus pneumoniae infection: a Canadian

  2013cites this paper
• 25 – Pneumococcal conjugate vaccine and pneumococcal common protein vaccines

  2013cites this paper
• Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.

  2013cites this paper
• Streptococcus pneumoniae infection: a Canadian perspective

  2013cites this paper
• Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

  2012cites this paper
• Serotype replacement in disease following pneumococcal vaccination : A discussion of the evidence

  2012cites this paper
• Eradication of Invasive Pneumococcal Disease due to the Seven-valent Pneumococcal Conjugate Vaccine Serotypes in Calgary, Alberta

  2012cites this paper
• Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections.

  2012cites this paper
• Baseline Epidemiology of Streptococcus pneumoniae Serotypes in Canada Prior to the Introduction of the 13-Valent Pneumococcal Vaccine

  2012cites this paper
• Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

  2012cites this paper
• The relationship between pneumococcal serotypes and antibiotic resistance.

  2012cites this paper
• Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.

  2012cites this paper
• Estudo das propriedades adjuvantes da vacina celular pertussis em combinação com o antígeno PspA de Streptococcus pneumoniae.

  2012cites this paper
• Considerations for controlling invasive meningococcal disease in high income countries.

  2012cites this paper
• Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

  2012cites this paper
• Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010.

  2012cites this paper
• Patients’ Preferences and Trade Offs for the Treatment of Small Hepatocellular Carcinomas

  2012cites this paper
• Controlled Inflammatory Responses in the Lungs Are Associated with Protection Elicited by a Pneumococcal Surface Protein A-Based Vaccine against a Lethal Respiratory Challenge with Streptococcus pneumoniae in Mice

  2012cites this paper
• The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

  2012influential citation
• The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults

  2012cites this paper
• Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010

  2012cites this paper
• Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates

  2012cites this paper
• Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood.

  2011cites this paper
• Rapport coût-efficacité des vaccins antipneumococciques conjugués 10- valent et 13-valent chez l’enfant

  2011cites this paper
• Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine

  2011cites this paper
• Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice.

  2011cites this paper
• Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.

  2011cites this paper
• The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci

  2011cites this paper
• Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination

  2011cites this paper
• Update on the success of the pneumococcal conjugate vaccine.

  2011cites this paper
• Optimizing Canadian public immunization programs: a prescription for action.

  2011cites this paper
• Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumoniae isolates in Japan

  2011cites this paper
• The future of pneumococcal disease prevention.

  2011cites this paper
• The dangerous synergism between influenza and Streptococcus pneumoniae and innovative perspectives of vaccine prevention.

  2011influential citation